MedTrace Logo

Headache Inducing Effect of Levcromakalim in Migraine With Aura Patients

NCT04012047 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2020-03-02

No results posted yet for this study

Summary

To investigate the role of KATP channels in migraine with aura patients.

Conditions

Interventions

DRUG

Levcromakalim

To investigate the role of levcromakalim compared with placebo in migraine with aura patients

DRUG

Saline

To investigate the role of levcromakalim compared with placebo in migraine with aura patients

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Principal Investigators

  • Messoud Ashina · Danish Headache Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-09
Primary Completion
2019-12-10
Completion
2019-12-10

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04012047 on ClinicalTrials.gov